AHA FIT Newsletter
Late-Breaking Clinical Trials at Scientific Sessions - Fall 2021 issue
Late-Breaking Clinical Trials at Scientific Sessions
Zakaria Almuwaqqat, MD
Cardiology Fellow, PGY-6
Division of Cardiology, Emory School of Medicine
While we look forward to the AHA Scientific Sessions, we as fellows are particularly excited to see the fascinating science coming out of the major trials in the Late-Breaking Science sessions. The first session will be focused on invasive cardiology studies. On Saturday, Nov. 13 at 9:30 AM ET, the first LBS session will explore four main trials: the utility of aortic valve replacement in patients with asymptomatic aortic stenosis will be presented in the AVATAR trial. While the RAPID CABG trial will present data comparing early versus standard coronary artery bypass surgery among patients presenting with acute coronary syndromes treated with Ticagrelor. Moreover, we look forward to receiving updates from the VEST Trial regarding the efficacy and safety of an external support device for saphenous vein coronary bypass grafts. Finally, we also look forward to seeing data regarding the benefit of concomitant tricuspid repair during mitral valve surgery. The second session will be presented in the same day at 3:00 PM ET and will feature results from the China Rural Hypertension Control Project (CRHCP): a cluster randomized trial of a village doctor-led intervention on blood pressure control. Additionally, a study of a remotely delivered hypertension and lipid program in 10,000 patients across a diverse health care network will be presented. Finally, results from 24 U.S. Health Systems in the PCORnet Blood Pressure Control Laboratory (BP Track) evaluating disruption in Blood Pressure Control with the COVID-19 Pandemic will be presented.
LBS on Sunday, Nov. 14 at 8 AM ET will focus on atrial arrhythmias; The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) trial results will be released and the GIRAF trial will post some data comparing dabigatran versus warfarin on cognitive outcomes in nonvalvular atrial fibrillation. After that Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation after Cardiac Surgery (PALACS) will be presented. Finally, the AMAZE trial will present outcomes of adjunctive left atrial appendage ligation utilizing the LARIAT compared to pulmonary vein antral isolation alone.
Later the same day at 2:45 PM ET another session will focus on digital health and using information technology in health care delivery. Results from three trials will be featured: the Risk Evaluation and its Impact on Clinical Decision-Making and Outcomes in Heart Failure (REVeAL-HF). The Fitbit Heart Study will present results regarding the detection of atrial fibrillation in a large population using wearable devices. Interestingly, the I-STOP-AF is a randomized trial that will focus on the individualized triggers of atrial fibrillation. In the heart failure world, there are many interesting trials that will be presented on 11/14 at 4 PM ET including the EMPEROR-Preserved Clinical Trial regarding empagliflozin use in patients with heart failure and preserved ejection fraction. Then, results from the Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure trial (CHIEF-HF) will be released and then the Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients (EMPULSE) trial will be released. Finally, the DREAM-HF will release data from the randomized trial of targeted trans-endocardial delivery of mesenchymal precursor cells in high-risk chronic heart failure patients with reduced ejection fraction.
On Monda, Nov. 15, in first session at 8 AM ET, PREPARE-IT 2 will present data regarding Icosapnt Ethyl versus placebo in outpatients with Covid-19. Then the COSMOS will Primary Findings from the Cocoa Supplement and Multivitamin Outcomes Study on the Prevention of Cardiovascular Disease. Another will explore the Clinical Safety, Pharmacokinetics and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor. Finally, at 11 AM ET, the ASCEND trial will describe the effect of Aspirin on Dementia and Cognitive Impairment. The ACTIVE 4A trial data will show the efficacy and safety of P2y12 Inhibitors in Noncritically Ill Hospitalized Patients with Covid-19. The REVERSE-IT trial will highlight the efficacy of Bentracimab on Hemostasis in Ticagrelor patients with uncontrolled hemorrhage or requiring urgent surgery and finally the AXIOMATIC-TKR Study will describe Milvexian for prevention of venous thromboembolism after elective knee arthroplasty.
| Date/Time | Session/Topic |
|---|---|
| Nov. 13 | Valves, Veins and New Viewpoints in Cardiothoracic Surgery |
| 9:30–10:30 AM ET | Aortic Valve Replacement Versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial |
| Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery | |
| A Randomized Study of Early Versus Standard Coronary Artery Bypass Surgery Among Patients Presenting with Acute Coronary Syndromes Treated with Ticagrelor (RAPID CABG) | |
| Efficacy and Safety of an External Support Device for Saphenous Vein Coronary Bypass Grafts: The VEST Trial | |
| Nov. 13 | Hypertension: Local, Global and Pandemic Impacts |
| 3–4 PM ET | A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network |
| Disruption in Blood Pressure Control with the COVID-19 Pandemic: A Study of 24 U.S. Health Systems in the PCORnet Blood Pressure Control Laboratory (BP Track) | |
| A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project (CRHCP) | |
| Nov 14 | Prevention to Intervention in Atrial Arrhythmias |
| 8–9 AM ET | The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) Trial |
| Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of the GIRAF Trial | |
| Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS) | |
| Outcomes of Adjunctive Left Atrial Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial | |
| Nov 14 | Information Overload? Striving to Improve Care Delivery Through Digital Health and Automated Data |
| 2:45–3:45 PM ET | Risk Evaluation and its Impact on Clinical Decision-Making and Outcomes in Heart Failure: The REVeAL-HF Trial |
| Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study | |
| Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib) | |
| Nov 14 | Building on the Foundations of Treatment: Advances in Heart Failure Therapy |
| 4–5PM ET | Heart Failure With a Preserved Ejection Fraction 50% - Results From the EMPEROR-Preserved Clinical Trial |
| The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial | |
| Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial | |
| Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients with Reduced Ejection Fraction (DREAM-HF) | |
| Nov 15 | Fish Oil, Cocoa and Cholesterol: Recipes for CVD Prevention? |
| 8–9 AM ET | Icosapent Ethyl Versus Placebo in Outpatients with Covid-19: The Main Results of PREPARE-IT 2 |
| Primary Findings from the Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) on the Prevention of Cardiovascular Disease | |
| The Clinical Safety, Pharmacokinetics and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor | |
| Nov 15 | New Drugs and New Drug Indications in Cardiovascular Disease |
| 11 AM–noon ET | Effects of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial |
| P2y12 Inhibitors in Noncritically Ill Hospitalized Patients with Covid-19 (ACTIV-4A) | |
| Effect Of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients with Uncontrolled Hemorrhage or Requiring Urgent Surgery in the REVERSE-IT | |
| Milvexian for Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study |